Brind.
  1. MIPLYFFA® and Zevra Therapeutics presented new clinical data on a drug targeting the underlying pathology of Niemann-Pick disease type C at the International Congress of Inborn Errors of Metabolism.

Zevra Therapeutics, which treats NPC with MIPLYFFA, announced that the enrollment for the drug included patients in Puerto Rico. Neil McFarlane is the company's CEO.

1 report, 1 independent Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Zevra Therapeutics, which treats NPC with MIPLYFFA, announced that the enrollment for the drug included patients in Puerto Rico. Neil McFarlane is the company's CEO.

Who's involved

What this event is mainly about
Neil McFarlanePuerto RicoNPC

Keep exploring

Part of

MIPLYFFA® and Zevra Therapeutics presented new clinical data on a drug targeting the underlying pathology of Niemann-Pick disease type C at the International Congress of Inborn Errors of Metabolism. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped